 |
|
|
| |
The safety and efficacy of maintenance with
doravirine/lamivudine/tenofovir through 192 weeks
in adults with HIV-1: Results from the DRIVE-AHEAD clinical trial
|
| |
| |
IAS 2021 - the 11th IAS Conference on HIV Science|18-21 JULY 2021
Chloe Orkin1; Jean-Michel Molina2; Khuanchai Supparatpinyo3; Sushma Kumar4; Hong Wan4; Valerie Teal4; Ernest Asante-Appiah4; Peter Sklar4; Hedy Teppler4; Rima Lahoulou5
1Queen Mary University of London, London, UK; 2Saint-Louis Hospital and University of Paris, Paris, France; 3Chiang Mai University, Chiang Mai, Thailand; 4Merck & Co., Inc., Kenilworth, NJ, USA; 5MSD France, Puteaux, France
|
| |
|
|
|
|
|
